Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Daxor Corporation - Closed End Fund (NQ:DXR)

8.591 -0.039 (-0.45%)
Streaming Delayed Price Updated: 3:47 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Daxor Corporation - Closed End Fund

Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
From Daxor Corporation
Via GlobeNewswire
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
From Daxor Corporation
Via GlobeNewswire
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
From Daxor Corporation
Via GlobeNewswire
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
From Daxor Corporation
Via GlobeNewswire
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
From Daxor Corporation
Via GlobeNewswire
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
From Daxor Corporation
Via GlobeNewswire
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
From Daxor Corporation
Via GlobeNewswire
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
From Daxor Corporation
Via GlobeNewswire
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
From Daxor Corporation
Via GlobeNewswire
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
From Daxor Corporation
Via GlobeNewswire
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
From Daxor Corporation
Via GlobeNewswire
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
From Daxor Corporation
Via GlobeNewswire
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
From Daxor Corporation
Via GlobeNewswire
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.